Syndax Pharmaceuticals Stock Earns RS Rating Upgrade

Core Insights - Syndax Pharmaceuticals (SNDX) received a Relative Strength (RS) Rating upgrade from 69 to 76, indicating improved technical performance and market leadership [1][4]. Company Performance - The RS Rating upgrade reflects a positive trend in Syndax Pharmaceuticals' stock performance, suggesting it is gaining traction in the market [1][2]. - The RS Rating is part of a scoring system that ranges from 1 (worst) to 99 (best), highlighting the stock's relative strength compared to others [1]. Market Context - The upgrade comes amid a broader market environment that is seeing increased buying activity, with other companies like Argenx and VanEck Semi also in focus [4]. - The market is experiencing a boost, which may provide additional support for stocks like Syndax Pharmaceuticals [4].